President and Chief Executive Officer · Corvus Pharmaceuticals, Inc. (CRVS)

Richard Miller

A named executive officer of Corvus Pharmaceuticals in every fiscal year CompBrief holds from FY2017 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$7,031,566

Salary $36,566Stock awards $0

FY2024: $3,073,170

1st of 3 named executive officers at Corvus Pharmaceuticals by FY2025 total.

3 named officers on file for Corvus Pharmaceuticals, FY2025

Richard Miller’s pay file — $29

  • 9 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Corvus Pharmaceuticals’s whole pay program stands against its peers

  • Corvus Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CRVS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Richard Miller’s full pay file as a PDF — free

More than this page: up to 10 years of Richard’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Richard Miller compensation by year

Corvus Pharmaceuticals Summary Compensation Table · all 9 fiscal years held
In US dollars, as Corvus Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Salary$301,837$302,961$300,000$300,000$300,000$300,000$110,309$32,675$36,566
Bonus$0$0$0$0$0$0$0$0$0
Stock awards$0$0$0$0$0$0$0$0$0
Option awards$948,765$1,056,352$795,039$885,297$602,085$218,239$1,205,042$3,034,495$6,989,000
Non-equity incentive$0$0$0$0$0$0$0$0$0
Pension and deferred compensation$0$0$0$0$0$0$0$0—
All other$2,000$3,000$3,000$3,000$3,000$6,000$6,000$6,000$6,000
Total$1,252,602$1,362,313$1,098,039$1,188,297$905,085$524,239$1,321,351$3,073,170$7,031,566

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Corvus Pharmaceuticals, Inc. DEF 14A filed April 24, 2026, accession 0001104659-26-048595, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Corvus Pharmaceuticals, Inc. filed document, accession 0001104659-26-048595. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2026.

$1.3M
$1.4M
$1.1M
$1.2M
$905K
$524K
$1.3M
$3.1M
$7.0M
FY17
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
SalaryOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option1,000,000—$8.81
Option53,333—$0.96
Option66,666—$0.91
Option166,666—$1.64
Option500,000—$4.99

Per the Outstanding Equity Awards at Fiscal Year-End table in Corvus Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

2 Form 4 lines since the FY2025 proxy (filed April 24, 2026)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-05-18Purchase—5,000$12.051,193,103
2026-05-18Purchase—1,932$12.011,195,035

The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Corvus Pharmaceuticals’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Richard Miller · this pagePresident and Chief Executive Officer$7,031,566
Leiv LeaChief Financial Officer$3,207,548
William JonesSenior Vice President, Pharmaceutical Development$3,161,715

Board service

Corvus Pharmaceuticals board · FY2023–FY2025

How this board is paid

Company policy: Corvus Pharmaceuticals pays directors a $35,000 cash retainer. As stated in Corvus Pharmaceuticals's FY2025 proxy.

Committees

Compensation (Chair) · Nominating/Governance

The full Corvus Pharmaceuticals compensation record

free company brief

This page is one person within Corvus Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Corvus Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Richard Miller's compensation dossier · One-time report. No refunds.